Allogene Therapeutics Future Growth
Future criteria checks 2/6
Allogene Therapeutics wird ein jährliches Wachstum der Erträge und Einnahmen um 6.6% bzw. 61.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 12.5% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -91.4% betragen.
Key information
9.1%
Earnings growth rate
14.6%
EPS growth rate
| Biotechs earnings growth | 20.8% |
| Revenue growth rate | 59.6% |
| Future return on equity | -96.6% |
| Analyst coverage | Good |
| Last updated | 25 Mar 2024 |
Recent future growth updates
Recent updates
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Allogene Therapeutics: Multibagger Potential, But Terribly Risky
Jun 24Allogene: Leading The Allogeneic CAR-T Space, Again
Apr 01Allogene: Lifting Of The Clinical Hold Will Be A Major Binary
Jan 12We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Nov 05Ramifications Of Allogene's Clinical Hold: Possible Sector-Wide Implications
Oct 19Allogene Therapeutics: I Am Buying On The Clinical Hold Dip
Oct 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 44 | -329 | -214 | -254 | 8 |
| 12/31/2025 | 4 | -305 | -216 | -221 | 15 |
| 12/31/2024 | 0 | -283 | -211 | -218 | 16 |
| 12/31/2023 | 0 | -327 | -239 | -238 | N/A |
| 9/30/2023 | 0 | -333 | -249 | -246 | N/A |
| 6/30/2023 | 0 | -355 | -241 | -238 | N/A |
| 3/31/2023 | 0 | -351 | -223 | -219 | N/A |
| 12/31/2022 | 0 | -340 | -226 | -221 | N/A |
| 9/30/2022 | 0 | -313 | -208 | -204 | N/A |
| 6/30/2022 | 0 | -308 | -212 | -205 | N/A |
| 3/31/2022 | 0 | -304 | -221 | -204 | N/A |
| 12/31/2021 | 114 | -182 | -206 | -185 | N/A |
| 9/30/2021 | 38 | -251 | -187 | -149 | N/A |
| 6/30/2021 | 38 | -239 | -193 | -138 | N/A |
| 3/31/2021 | 38 | -229 | -184 | -124 | N/A |
| 12/31/2020 | N/A | -316 | -181 | -115 | N/A |
| 9/30/2020 | N/A | -243 | -218 | -155 | N/A |
| 6/30/2020 | N/A | -227 | -211 | -150 | N/A |
| 3/31/2020 | N/A | -207 | -201 | -148 | N/A |
| 12/31/2019 | N/A | -185 | -188 | -137 | N/A |
| 9/30/2019 | N/A | -154 | -147 | -109 | N/A |
| 6/30/2019 | N/A | -147 | -115 | -94 | N/A |
| 3/31/2019 | N/A | -240 | -91 | -75 | N/A |
| 12/31/2018 | N/A | -212 | -50 | -45 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: ALLO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: ALLO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: ALLO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: ALLODie Einnahmen des Unternehmens (72.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.1% pro Jahr).
Hohe Wachstumseinnahmen: ALLODie Einnahmen des Unternehmens (72.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: ALLO wird voraussichtlich in 3 Jahren unrentabel sein.